In Vivo FRET Imaging to Predict the Risk Associated with Hepatic Accumulation of Squalene-Based Prodrug Nanoparticles.

Fanny Cayre (1) , Simona Mura (2) , Bohdan Andreiuk (3) , Dunja Sobot (2) , Sandrine Gouazou , Didier Desmaele (2) , Andrey Klymchenko (3) , Patrick Couvreur (4)

1 Novartis Pharma
2 IGPS - Institut Galien Paris-Sud
3 LBP - Laboratoire de Biophotonique et Pharmacologie - UMR 7213
4 PCPB - Physico-chimie, pharmacotechnie, biopharmacie

Förster resonance energy transfer (FRET) is used here for the first time to monitor the in vivo fate of nanoparticles made of the squalene-gemcitabine prodrug and two novel derivatives of squalene with the cyanine dyes 5.5 and 7.5, which behave as efficient FRET pair in the NIR region. Following intravenous administration, nanoparticles initially accumulate in the liver, then they show loss of their integrity within 2 h and clearance of the squalene bioconjugates is observed within 24 h. Such awareness is a key prerequisite before introduction into clinical settings.

Mots clés: FRET; Prodrug nanoparticles; In vivo non-invasive imaging; FRET

Domaines: Autre [q-bio.OT]

Fanny Cayre, Simona Mura, Bohdan Andreiuk, Dunja Sobot, Sandrine Gouazou, et al.. In Vivo FRET Imaging to Predict the Risk Associated with Hepatic Accumulation of Squalene-Based Prodrug Nanoparticles.. Advanced healthcare materials, 2017, 7 (3), pp.1700830. ⟨10.1002/adhm.201700830⟩. ⟨hal-02347607⟩